ReviewFrontiers in pharmacology2026
From gluten to therapeutics: molecular mechanisms of celiac disease and emerging alternatives to the gluten-free diet.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Celiac disease (CD) is a chronic immune-mediated disorder triggered by gluten ingestion in genetically predisposed individuals. Increasing knowledge regarding gluten-derived peptides, intestinal barrier dysfunction, innate and adaptive immune responses, and host-microbiota interactions has substantially improved our understanding of disease pathogenesis and stimulated the development of novel therapeutic strategies. The present review aims to provide an integrated overview of the biochemical, immunological, clinical, and therapeutic aspects of CD by linking its molecular mechanisms to the rationale underlying emerging treatment approaches. Particular attention is devoted to the roles of toxic and immunogenic gluten peptides, tissue transglutaminase, intestinal permeability, and immune activation as potential therapeutic targets. Although the gluten-free diet remains the only established treatment, long-term adherence is often challenging and may negatively affect the nutritional status and quality of life while posing an economic burden. Consequently, several alternative or adjunctive approaches have been investigated, including gluten-degrading enzymes, transglutaminase 2 inhibitors, immune-targeted therapies, microbiota modulation, genetically modified cereals, and other experimental interventions. Current evidence suggests that several of these strategies show promising preclinical or early clinical results; however, most of these approaches are limited by insufficient efficacy data, small clinical studies, regulatory challenges, or lack of long-term safety information. At present, none of these approaches can replace the gluten-free diet in routine clinical practice. Overall, the future management of CD will likely require personalized and potentially combined therapeutic approaches. Further translational and clinical studies are needed to identify safe, effective, and accessible alternatives capable of complementing or reducing the burden of lifelong dietary treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.